| Předmět: |
|
| Zdroj: |
Drug Week; 9/6/2024, p391-391, 1p |
| Abstrakt: |
Researchers at Carnegie Mellon University have developed therapeutic gentamicin methacrylic comonomers (gMAs) for use in bone cements to combat prosthetic joint infections. These comonomers integrate into poly (methyl methacrylate) (PMMA) bone cements, providing mechanical strength and sustained drug release. In vitro and in vivo testing has shown that the gMA-loaded cement effectively inhibits biofilm formation and reduces bacterial count, surpassing the impact of systemic antibiotic treatment in mice. This innovative approach has the potential to transform the treatment of implant-associated infections by providing bone cements that are both mechanically robust and able to treat infections. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
